Download PDF
Thromb Haemost 2004; 91(03): 423-424
DOI: 10.1055/s-0037-1614286
Editorial Focus
Schattauer GmbH

Fibrinolysis and proteolysis in a cellular context

Klaus T. Preissner
1   Institute for Biochemistry, Medical Faculty, Justus Liebig University, Giessen, Germany
,
Raymund Machovich
2   Semmelweiss University, Department of Medical Biochemistry, Budapest, Hungary
› Author Affiliations
Further Information

Publication History

Received 19 January 2004

Accepted 19 January 2004

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Nar H, Bauer M, Stassen JM. et al.. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 2000; 297: 683-95.
    CrossrefPubMedGoogle Scholar
  • 2 Carmeliet P, Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 2000; 190: 387-405.
    CrossrefPubMedGoogle Scholar
  • 3 Ploplis VA, Castellino FJ. Gene targeting of components of the fibrinolytic system. Thromb Haemost 2002; 87: 22-31.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation 2003; 107: 2533-7.
    CrossrefPubMedGoogle Scholar
  • 5 Preissner KT, Nawroth PP, Kanse SM. Vascular protease receptors: integrating haemostasis and endothelial cell functions. J Pathol 2000; 190: 360-72.
    CrossrefPubMedGoogle Scholar
  • 6 Ling Q, Jacovina AT, Deora A. et al.. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48.
    CrossrefPubMedGoogle Scholar
  • 7 Maskos K, Bode W. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Mol Biotechnol 2003; 25: 241-66.
    CrossrefPubMedGoogle Scholar
  • 8 Bobik A, Tkachuk V. Metalloproteinases and plasminogen activators in vessel remodeling. Curr Hypertens Rep 2003; 05: 466-72.
    CrossrefPubMedGoogle Scholar
  • 9 Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 2003; 54: 101-23.
    PubMedGoogle Scholar
  • 10 Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 1998; 89: 1-21.
    CrossrefPubMedGoogle Scholar
  • 11 Wind T, Hansen M, Jensen JK. et al.. The molecular basis for anti-proteolytic and nonproteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol Chem 2002; 383: 21-36.
    PubMedGoogle Scholar
  • 12 Gils A, Declerck PJ. Structure, function and pathophysiological relevance of plasminogen activator inhibitor-1. Thromb Haemost 2004; 91: 425-37.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Juhan-Vague I, Alessi MC, Mavri A. et al.. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 01: 1575-9.
    CrossrefPubMedGoogle Scholar
  • 14 Luttun A, Lupu F, Storkebaum E. et al.. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22: 499-505.
    CrossrefPubMedGoogle Scholar
  • 15 Rakic JM, Maillard C, Jost M. et al.. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003; 60: 463-73.
    CrossrefPubMedGoogle Scholar
  • 16 Chavakis T, Kanse SM, May AE. et al.. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation. Biochem Soc Trans 2002; 30: 168-73.
    CrossrefPubMedGoogle Scholar
  • 17 Durand MKV, Bødker JS, Christensen A. et al.. Plasminogen activator inhibitor-1 and tumour growth, invasion and metastasis. Thromb Haemost 2004; 91: 438-49.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Harbeck N, Kates RE, Gauger K. et al.. Urokinase-type plasminogen activator uPA and its inhibitor PAI-1 are the first novel tumor biological factors to reach the highest level of evidence for their clinical relevance in breast cancer. Thromb Haemost 2004; 91: 450-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Krol J, Sato S, Rettenberger P. et al.. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol Chem 2003; 384: 1085-96.
    PubMedGoogle Scholar
  • 20 Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet 2003; 04: 710-20.
    CrossrefPubMedGoogle Scholar
  • 21 Yepes M, Sandkvist M, Wong MK. et al.. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569-76.
    PubMedGoogle Scholar
  • 22 Strickland S. Tissue plasminogen activator in nervous system: function and dysfunction. Thromb Haemost 2001; 86: 138-43.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Yepes M, Lawrence DA. Neuroserpin: A selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost 2004; 91: 457-64.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89: 610-21.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Podor TJ, Singh D, Chindemi P. et al.. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002; 277: 7529-39.
    CrossrefPubMedGoogle Scholar
  • 26 Kolev K, Tenekedjiev K, Ajtai K. et al.. Myosin: a noncovalent stabilizer of fibrin in the process of clot dissolution. Blood 2003; 101: 4380-6.
    CrossrefPubMedGoogle Scholar